


**Amendments to the specification:**


Please delete the paragraph beginning on line 21 page 6 and ending on line 26 page 7 and replace with the following:

In a further aspect of the invention there is provided a process for preparing compounds of formula (I), or a pharmaceutically acceptable derivative thereof, which process comprises:

(a) reacting a compound of formula (IV) with a compound of formula (V):



(IV)



(V)


wherein  $Z^1$ ,  $Z^2$ ,  $Z^3$ ,  $Z^4$  and  $Z^5$ ,  $m$ ,  $n$ ,  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are as defined in formula (I), and  $X$  and  $Y$  may be the following combinations:

- (i)  $X$  is  $M$  and  $Y$  is  $CH_2CO_2R^X$
- (ii)  $X$  is  $CO_2RY$  and  $Y$  is  $CH_2CO_2R^X$
- (iii) one of  $X$  and  $Y$  is  $CH=SPh_2$  and the other is  $CHO$
- (iv)  $X$  is  $CH_3$  and  $Y$  is  $CHO$
- (v)  $X$  is  $CH_3$  and  $Y$  is  $CO_2R^X$
- (vi)  $X$  is  $CH_2CO_2RY$  and  $Y$  is  $CO_2R^X$
- (vii)  $X$  is  $CH=PR^Z_3$  and  $Y$  is  $CHO$
- (viii)  $X$  is  $CHO$  and  $Y$  is  $CH=PR^Z_3$
- (ix)  $X$  is halogen and  $Y$  is  $CH=CH_2$
- (x) one of  $X$  and  $Y$  is  $COW$  and the other is  $NHR^{11'}$  or  $NCO$
- (xi) one of  $X$  and  $Y$  is  $(CH_2)_p-V$  and the other is  $(CH_2)_qNHR^{11'}$ ,  $(CH_2)_qOH$ ,  $(CH_2)_qSH$  or  $(CH_2)_qSCOR^X$  where  $p+q=1$
- (xii) one of  $X$  and  $Y$  is  $CHO$  and the other is  $NHR^{11'}$
- (xiii) one of  $X$  and  $Y$  is  $OH$  and the other is  $-CH=N_2$

in which  $V$  and  $W$  are leaving groups,  $R^X$  and  $RY$  are  $(C_{1-6})alkyl$  and  $R^Z$  is aryl or  $(C_{1-6})alkyl$ ;

or

(b) reacting a compound of formula (IV) with a compound of formula (Vb):



wherein  $Z^1$ ,  $Z^2$ ,  $Z^3$ ,  $Z^4$  and  $Z^5$ ,  $m$ ,  $n$ ,  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are as defined in formula (I),  $X$  is  $CH_2NHR^{11'}$  and  $Y$  is  $CHO$  or  $COW$  or  $X$  is  $CH_2OH$  and  $Y$  is  $-CH=N_2$ ;

in which  $R^{11'}$ ,  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are  $R^{11}$ ,  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  or groups convertible thereto, and thereafter optionally or as necessary converting  $R^{11'}$ ,  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  to  $R^{11}$ ,  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$ , converting A-B to other A-B, interconverting  $R^{11}$ ,  $R^1$ ,  $R^2$ ,  $R^3$  and/or  $R^4$  and forming a pharmaceutically acceptable derivative thereof.

Please delete the paragraph beginning on line 29 page 3 and ending on line 36 page 3 and replace with the following:

When  $R^1$  is substituted alkoxy it is preferably  $C_{2-6}$  alkoxy substituted by optionally N-substituted amino, guanidino or amidino, more preferably by amino, or  $C_{1-6}$  alkoxy substituted by piperidyl. Suitable examples of  $R^1$  alkoxy include methoxy, n-propyloxy, i-butyloxy, aminoethoxy, aminopropyloxy, aminopentyloxy, guanidinopropyloxy, piperidin-4-ylmethoxy, phthalimido-pentyloxy or 2-aminocarbonylprop-2-oxy. ~~Preferably  $R^1$  is in the 6-position on the quinoline nucleus.~~ Preferably  $R^1$  is methoxy, amino( $C_{3-5}$ )alkyloxy, nitro or fluoro, most preferably methoxy.

Please delete the title compound name for Example 7 starting on page 26, line 27 and ending on page 27, line 28 and replace with the following:

**Example 7. [3R,4S]-1-Heptyl-4-N-(6-methoxy-1,5-naphthyridin-4-yl)-3-(1-(R/S)- 2-dihydroxyethyl)-piperidineacetamide oxalate**

Please add the priority information paragraph to the specification by inserting the following new paragraph before the first line of the specification:

This application is a continuation of U.S. application serial no. 09/807,275 filed April 11, 2001 which is a 371 of PCT/GB99/03366, filed October 11, 1999.

An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Please insert the attached abstract, following the claims.